Full Text View
Tabular View
No Study Results Posted
Related Studies
RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization
This study has been terminated.
( The study was terminated after the EMEA recommended to suspend the marketing authorisation of Raptiva in the EU )
Study NCT00402818   Information provided by Merck KGaA

First Received on November 20, 2006.   Last Updated on December 15, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Plaque Psoriasis
Additional conditions recognized in this trial
Psoriasis
More general conditions related to this trial
Skin Diseases
Skin Diseases, Papulosquamous
Sponsors listed in this trial
Merck KGaA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services